Masimo (MASI) Expected to Announce Earnings on Tuesday

Masimo (NASDAQ:MASI) is projected to release its earnings data after the market closes on Tuesday, February 25th. Analysts expect Masimo to post earnings of $1.42 per share and revenue of $593.35 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Masimo Price Performance

MASI stock opened at $169.96 on Friday. Masimo has a 52 week low of $101.61 and a 52 week high of $184.51. The firm has a market capitalization of $9.10 billion, a P/E ratio of 117.21 and a beta of 1.02. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The company has a fifty day simple moving average of $172.78 and a two-hundred day simple moving average of $152.03.

Analyst Upgrades and Downgrades

MASI has been the topic of several recent analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research note on Wednesday, January 22nd. Stifel Nicolaus reissued a “buy” rating and issued a $190.00 target price (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Wells Fargo & Company increased their target price on shares of Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Piper Sandler increased their target price on shares of Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th. Finally, Raymond James raised their price target on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research note on Friday, December 27th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Masimo currently has an average rating of “Moderate Buy” and an average price target of $191.40.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.